In contrast, our meta-analysis, as well as the previous ones [56,57,58,59] confirms that the combination of CDK4/6 inhibitors and ET yields a very high rate of tumour regression, which is on average as high as 55% for patients with measurable disease, with no heterogeneity among different compounds. This evidence concerns the gene CDK4 and neoplasm.